Aclaris Therapeutics, Inc.
ORAL COMPOSITIONS OF MK2 PATHWAY INHIBITOR FOR TREATMENT OF IMMUNE CONDITIONS
Last updated:
Abstract:
The present disclosure relates to oral compositions of Compound I or a derivative thereof. Methods of use for treating an inflammatory condition are also disclosed.
Status:
Application
Type:
Utility
Filling date:
26 Mar 2021
Issue date:
4 Nov 2021